Chronic Spontaneous Urticaria (CSU)
References
1. Zuberbier, T., et al., The international EAACI/GA(2)LEN/EuroGuiDerm/AP AAACI guideline for the definition, classification, diagnosis, and management of urticaria.
Allergy, 2022. 77(3): p. 734-766.
2. Greaves, M., Chronic urticaria. J Allergy Clin Immunol, 2000. 105(4): p. 664-72.
3. Kolkhir, P., et al., Urticaria. Nat Rev Dis Primers, 2022. 8(1): p. 61.
4. Buttgereit, T., et al., Patients With Chronic Spontaneous Urticaria Who Have Wheals,
Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment
Results From CURE. J Allergy Clin Immunol Pract, 2023. 11(11): p. 3515-3525 e4.
5. Balp, M.M., et al., Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted
Literature Review. Dermatol Ther (Heidelb), 2022. 12(1): p. 15-27.
6. Sussman, G., et al., Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE-CSU. Allergy, 2018. 73(8): p. 1724- 1734.
7. Kovalkova, E., et al., Comorbid Inducible Urticaria Is Linked to Non-Autoimmune
Chronic Spontaneous Urticaria: CURE Insights. J Allergy Clin Immunol Pract, 2024.
12(2): p. 482-490 e1.
8. Sijapati, N., et al., Exercise-Induced Urticaria: A Rare Case Report. Cureus, 2022. 14(3): p.
e23062.
9. V olcheck, G.W. and J.T. Li, Exercise-induced urticaria and anaphylaxis. Mayo Clin Proc,
1997. 72(2): p. 140-7.
10. Kulthanan, K., et al., Food-dependent cold urticaria: A new variant of physical urticaria. J Allergy Clin Immunol Pract, 2018. 6(4): p. 1400-1402.
11. Maurer, M., et al., Efficacy and safety of omalizumab in patients with chronic urticaria
who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol, 2011. 128(1): p. 202-
209 e5.
12. Kolkhir, P., et al., Autoimmune chronic spontaneous urticaria. Journal of Allergy and
Clinical Immunology, 2022. 149(6): p. 1819-1831.
13. Schoepke, N., et al., Biomarkers and clinical characteristics of autoimmune chronic
spontaneous urticaria: Results of the PURIST Study. Allergy, 2019. 74(12): p. 2427-
2436.
14. Asero, R., et al., Activation of the tissue factor pathway of blood coagulation in patients
with chronic urticaria. J Allergy Clin Immunol, 2007. 119(3): p. 705-10.
15. Saini, S.S., et al., Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria. J Invest Dermatol, 2017. 137(4): p. 958-961.
16. Shakouri, A., et al., Effectiveness of Helicobacter pylori eradication in chronic urticaria:
evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol, 2010. 10(4): p. 362-9.
17. Confino-Cohen, R., et al., Chronic urticaria and autoimmunity: associations found in a
large population study. J Allergy Clin Immunol, 2012. 129(5): p. 1307-13.
18. Viracor, E. CU Index. 2013 12/APR/2024]; Available from: https://www.eurofins
viracor.com/clinical/test-menu/2103-cu-index/.
19. Biagtan, M.J., et al., Clinical utility of the Chronic Urticaria Index. J Allergy ClinImmunol, 2011. 127(6): p. 1626-7.
20. Sabroe, R.A., et al., British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021. Br J Dermatol, 2022. 186(3): p. 398-413.
21. Kulthanan, K., et al., Chronic idiopathic urticaria: prevalence and clinical course. J
Dermatol, 2007. 34(5): p. 294-301.
22. Siles, R., M. Xu, and F.H. Hsieh, The utility of serum tryptase as a marker in chronic
spontaneous urticaria. Acta Derm Venereol, 2013. 93(3): p. 354-5.
23. Ferrer, M., et al., Serum total tryptase levels are increased in patients with active chronic
urticaria. Clin Exp Allergy, 2010. 40(12): p. 1760-6.
24. Kasperska-Zajac, A., et al., Plasma IL-6 concentration correlates with clinical disease
activity and serum C-reactive protein concentration in chronic urticaria patients. Clin
Exp Allergy, 2011. 41(10): p. 1386-91.
25. Powell, R.J., et al., BSACI guideline for the management of chronic urticaria and
angioedema. Clin Exp Allergy, 2015. 45(3): p. 547-65.
26. Brown, T., J. Gonzalez, and C. Monteleone, Angiotensin-converting enzyme inhibitor
induced angioedema: A review of the literature. J Clin Hypertens (Greenwich), 2017.
19(12): p. 1377-1382.
27. Pfaar, O., et al., COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society
for Applied Allergology (AeDA). Allergol Select, 2021. 5: p. 140-147.
28. Kocaturk, E., et al., Effects of pregnancy on chronic urticaria: Results of the PREG-CU
UCARE study. Allergy, 2021. 76(10): p. 3133-3144.
29. Khan, D.A., Alternative agents in refractory chronic urticaria: evidence and
considerations on their selection and use. J Allergy Clin Immunol Pract, 2013. 1(5): p.
433-440 e1.
30. Bernstein, J.A., et al., The diagnosis and management of acute and chronic urticaria:
2014 update. J Allergy Clin Immunol, 2014. 133(5): p. 1270-7.
31. Kaplan, A.P., Therapy of chronic urticaria: a simple, modern approach. Ann Allergy
Asthma Immunol, 2014. 112(5): p. 419-25.
32. Kallen, B., Use of antihistamine drugs in early pregnancy and delivery outcome. J
Matern Fetal Neonatal Med, 2002. 11(3): p. 146-52.
33. Saini, S., et al., A randomized, placebo-controlled, dose-ranging study of single-dose
omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J
Allergy Clin Immunol, 2011. 128(3): p. 567-73 e1.
34. Metz, M., et al., Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. Clin Rev Allergy Immunol, 2020. 59(1): p. 38-45.
35. Metz, M., et al., Omalizumab is an effective and rapidly acting therapy in difficult-to treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci, 2014. 73(1): p. 57-62.
36. Barron, C., Saperia, C., Kobric, D., Sussman, G.L., Chronic spontaneous urticaria; Centres' of excellence. Journal of Allergy and Clinical Immunology, 2017. 139(2).
37. EAACI/ESCD Skin Allergy Meeting 2017. Clin Transl Allergy, 2017. 7(47).
38. Vadasz, Z., et al., Omalizumab for severe chronic spontaneous urticaria: Real-lifeexperiences of 280 patients. J Allergy Clin Immunol Pract, 2017. 5(6): p. 1743-1745.
39. Alizadeh Aghdam, M., et al., High-dose omalizumab use in patients with chronic
spontaneous urticaria. J Allergy Clin Immunol Pract, 2020. 8(4): p. 1426-1427 e1.
40. Kocaturk, E., et al., Omalizumab Updosing for Better Disease Control in Chronic
Spontaneous Urticaria Patients. Int Arch Allergy Immunol, 2018. 177(4): p. 360-364.
41. Curto-Barredo, L., et al., Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria. Br J Dermatol, 2018. 179(1): p. 210-212.
42. Salman, A. and E. Comert, The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria. J Cutan Med Surg, 2019. 23(5): p. 496-500.
43. Zhao, Z.T., et al., Omalizumab for the treatment of chronic spontaneous urticaria: A
meta-analysis of randomized clinical trials. J Allergy Clin Immunol, 2016. 137(6): p.
1742-1750 e4.
44. Maurer, M., et al., Omalizumab for the treatment of chronic idiopathic or spontaneous
urticaria. N Engl J Med, 2013. 368(10): p. 924-35.
45. Kaplan, A., et al., Omalizumab in patients with symptomatic chronic
idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin
Immunol, 2013. 132(1): p. 101-9.
46. Urgert, M.C., et al., Omalizumab in patients with chronic spontaneous urticaria: a
systematic review and GRADE assessment. Br J Dermatol, 2015. 173(2): p. 404-15.
47. Saini, S.S., et al., Efficacy and Safety of Omalizumab in Patients with Chronic
Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A
Randomized, Placebo-Controlled Study. J Invest Dermatol, 2015. 135(3): p. 925.
48. Staubach, P., et al., Effect of omalizumab on angioedema in H1 -antihistamine-resistant
chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Allergy, 2016. 71(8): p. 1135-44.
49. Metz, M., Staubach, P., Bauer, A., Brehler, R. , Omalizumab normalizes levels of high
affinity immunoglobulin E receptor-positive skin cells in patients with chronic
spontaneous urticaria: a randomized, double-blind, placebo-controlled study. J of
Investigative Derm, 2014. 134: p. S30-38.
50. Namazy, J., et al., The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol, 2015. 135(2): p. 407-12.
51. Kulthanan, K., et al., Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis
and Systematic Review. J Allergy Clin Immunol Pract, 2018. 6(2): p. 586-599.
52. Zimmerman, A.B., et al., The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol, 2012. 66(5): p. 767-70.
53. Sand, F.L. and S.F. Thomsen, Off-label use of TNF-alpha inhibitors in a dermatological
university department: retrospective evaluation of 118 patients. Dermatol Ther, 2015.
28(3): p. 158-65.
54. Bernstein, J.A., S.M. Garramone, and E.G. Lower, Successful treatment of autoimmune
chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma
Immunol, 2002. 89(2): p. 212-4.
55. Pho, L.N., et al., Treatment of chronic urticaria with colchicine. J Drugs Dermatol, 2011.10(12): p. 1423-8.
56. Kalogeromitros, D., et al., Theophylline as 'add-on' therapy to cetirizine in patients with
chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study.
Int Arch Allergy Immunol, 2006. 139(3): p. 258-64.
57. Asero, R., A. Tedeschi, and M. Cugno, Heparin and tranexamic Acid therapy may be
effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int
Arch Allergy Immunol, 2010. 152(4): p. 384-9.
58. Bressler, R.B., K. Sowell, and D.P. Huston, Therapy of chronic idiopathic urticaria with
nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled,
crossover trial. J Allergy Clin Immunol, 1989. 83(4): p. 756-63.
59. Rorie, A., et al., Beneficial role for supplemental vitamin D3 treatment in chronic
urticaria: a randomized study. Ann Allergy Asthma Immunol, 2014. 112(4): p. 376-82.
60. Maurer, M., et al., Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. The Lancet, 2024. 403(10422): p. 147-159.
61. ClinicalTrials.gov. A study of long-term effects of fenebrutinib treatment in patients with
chronic spontaneous urticaria. 2020 07/NOV/2024]; Available from:
https://clinicaltrials.gov/study/NCT03693625.
62. Genentech. Fenebrutinib multiple sclerosis clinical trial program update. 2023
07/NOV/2024]; Available from: https://www.gene.com/media/statements/ps_113023.
63. Metz, M., Gimenez-Amau, A., Hide, M., et al. . Long-term efficacy and safety of
remibrutinib in patietns with chronic spontaneous urticaria in the phase 3 REMIX-1 and
REMIX-2 studies. in EAACI. 2024. Valencia, Spain.
64. Jain, V ., et al., Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. Journal of Allergy and Clinical
Immunology, 2024. 153(2): p. 479-486.e4.
65. Maurer, M., et al., Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria
Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial. Journal of
Allergy and Clinical Immunology, 2024. 153(2): p. AB366.
66. Altrichter, S., Gimenez-Arnau, A.M., Bernstein, J.A. et al, Benralizumab does not elicit
therapeutic effect in patients with chronic spontaneous urticaria: Results form the phase
IIb multinational randomized double-blind placebo-controlled ARROYO trial. Br J
Dermatol, 2024. 191(2): p. 187-199.
67. ClinicalTrials.gov. A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines
(ARROYO). 13/APR/2024 11/NOV/2024].
68. Maurer, M., et al., Dupilumab in patients with chronic spontaneous urticaria (LIBERTY CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. Journal of
Allergy and Clinical Immunology, 2024. 154(1): p. 184-194.
69. Kudlaty, E., Newell, P., Chovatiya, R., et al., Dupilumab as add-on therapy for
management of chronic spontaneous urticaria. J Clin Aesthet Dermatol, 2024. 17: p. 10-
12.
70. Altrichter, S., Staubach, P., Pasha, M. et al, An open-label, proof-of-concept study of
lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. JAller Clin Immunol, 2022. 149(5): p. 1683-1690.
71. Bakay, O.S.K., Kacar, N., Combined treatment with omalizumab and secukinumab in a
patient with chronic spontaneous urticaria and psoriasis. Dermatol Ther, 2022. 35(9).
72. Sabag, D.A., Matanes, L., Bejar, J. et al, Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy, 2020. 50(7): p. 799-804.
73. Hatlen M, Haidle A, Wilson D, et al. BLU-808: A potent and selective oral small molecule wild-type KIT tyrosine kinase inhibitor for allergic conditions. Poster presented at: American Academy of Allergy Asthma & Immunology (AAAAI) / World Allergy Organization (WAO)
Joint Congress; March 1, 2025; San Diego, CA, USA
74. Casale TB. Briquilimab demonstrates rapid, clinically meaningful reduction in disease
activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study. Presented at: American Academy of Dermatology (AAD) Annual Meeting; March 8, 2025; Orlando, FL.